CN110087651A - 施用抗纤维化疗法的方法 - Google Patents

施用抗纤维化疗法的方法 Download PDF

Info

Publication number
CN110087651A
CN110087651A CN201780074290.6A CN201780074290A CN110087651A CN 110087651 A CN110087651 A CN 110087651A CN 201780074290 A CN201780074290 A CN 201780074290A CN 110087651 A CN110087651 A CN 110087651A
Authority
CN
China
Prior art keywords
compound
subject
food
ppi
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780074290.6A
Other languages
English (en)
Chinese (zh)
Inventor
潘林
D.S-W.张
J.M.哈里斯
I.斯特伦波姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN110087651A publication Critical patent/CN110087651A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780074290.6A 2016-11-30 2017-11-29 施用抗纤维化疗法的方法 Pending CN110087651A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662428163P 2016-11-30 2016-11-30
US62/428163 2016-11-30
US201662432425P 2016-12-09 2016-12-09
US62/432425 2016-12-09
PCT/US2017/063549 WO2018102323A1 (en) 2016-11-30 2017-11-29 Methods of administering anti-fibrotic therapy

Publications (1)

Publication Number Publication Date
CN110087651A true CN110087651A (zh) 2019-08-02

Family

ID=60655162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780074290.6A Pending CN110087651A (zh) 2016-11-30 2017-11-29 施用抗纤维化疗法的方法

Country Status (11)

Country Link
US (3) US11207304B2 (https=)
EP (2) EP4470624A3 (https=)
JP (3) JP2020502054A (https=)
KR (3) KR20230129628A (https=)
CN (1) CN110087651A (https=)
AU (3) AU2017366881A1 (https=)
CA (2) CA3247781A1 (https=)
IL (3) IL299447A (https=)
MX (3) MX2019006143A (https=)
TW (3) TW202539656A (https=)
WO (1) WO2018102323A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022048580A1 (zh) * 2020-09-03 2022-03-10 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207304B2 (en) 2016-11-30 2021-12-28 Genentech, Inc. Methods of administering anti-fibrotic therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055548A1 (en) * 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207304B2 (en) 2016-11-30 2021-12-28 Genentech, Inc. Methods of administering anti-fibrotic therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055548A1 (en) * 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
CN104822687A (zh) * 2012-10-02 2015-08-05 英特穆恩公司 抗纤维化吡啶酮类
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
P. ARNOLD, M. WERMEILLE等: "Influence of Food and Antacid Administration on Fluoride Bioavailability from Enter&coated Sodium Fluoride Tablets", 《BONE》 *
P.A.WINSTANLWY等: "The effects of food on drug bioavailability", 《BRITISH JOURNAL OF CLINICAL PHAMACOLOGY》 *
梁绪中等: "《临床药学与药物治疗学》", 30 June 2016, 吉林科学技术出版社 *
沈晓君等: "《病理病原学》", 28 February 2009, 河南科学技术出版社 *
熊彬等: "《呼吸内科疾病诊疗与用药指导》", 31 October 2015, 西安交通大学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022048580A1 (zh) * 2020-09-03 2022-03-10 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用

Also Published As

Publication number Publication date
TW202412795A (zh) 2024-04-01
US11925624B2 (en) 2024-03-12
JP2023139157A (ja) 2023-10-03
CA3247781A1 (en) 2025-07-09
IL266480A (en) 2019-07-31
TWI826361B (zh) 2023-12-21
IL289544A (en) 2022-03-01
IL299447A (en) 2023-02-01
CA3045455A1 (en) 2018-06-07
AU2023263548B2 (en) 2025-10-16
KR20190089862A (ko) 2019-07-31
AU2017366881A1 (en) 2019-05-30
AU2025238129A1 (en) 2025-10-23
JP2022058873A (ja) 2022-04-12
JP2020502054A (ja) 2020-01-23
MX2020011766A (es) 2020-11-24
IL289544B2 (en) 2023-06-01
US20240197693A1 (en) 2024-06-20
KR20230129628A (ko) 2023-09-08
KR20220139450A (ko) 2022-10-14
EP4470624A2 (en) 2024-12-04
TW201825093A (zh) 2018-07-16
EP4470624A3 (en) 2025-01-08
US11207304B2 (en) 2021-12-28
TW202539656A (zh) 2025-10-16
JP7495951B2 (ja) 2024-06-05
MX2023003924A (es) 2023-04-26
TWI891129B (zh) 2025-07-21
US12310951B2 (en) 2025-05-27
KR102575344B1 (ko) 2023-09-06
AU2023263548A1 (en) 2023-11-30
US20220184046A1 (en) 2022-06-16
WO2018102323A1 (en) 2018-06-07
US20190321344A1 (en) 2019-10-24
MX2019006143A (es) 2019-10-17
EP3548025A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
JP2024071605A (ja) ナルトレキソン療法における薬物バイオアベイラビリティの増加
US12310951B2 (en) Methods of administering anti-fibrotic therapy
US20220233520A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
HK40012787A (en) Methods of administering anti-fibrotic therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012787

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20190802

RJ01 Rejection of invention patent application after publication